This report is based on public company disclosures, filings and announcements reviewed by GSN; figures are as stated by the company and have not been independently verified.

Prescient Therapeutics (ASX: PTX) announced that it has reached a pre-specified enrolment threshold for its ongoing Phase 2a clinical study of its lead drug candidate, PTX-100. The company stated that 20 evaluable patients have now been enrolled in the trial evaluating the treatment for relapsed or refractory Cutaneous T-Cell Lymphoma (CTCL). This milestone formalises the timing for the study’s first planned Dose Optimisation Committee (DOC) review, which the company confirmed remains on track to convene in December 2026.

The Phase 2a study design evaluates two distinct dosing arms. Under the trial protocol, patients are deemed evaluable upon the completion of four treatment cycles. The company noted that 10 evaluable patients have been enrolled in each of the two dosing arms. The Dose Optimisation Committee, comprising clinical and biostatistical experts, is tasked with reviewing safety and efficacy data from both dosing cohorts to provide guidance on the continuation and design of further study development. Prescient Therapeutics highlighted that the December review represents a scheduled dose optimisation milestone within the ongoing trial rather than the completion of the Phase 2a study itself. International patient enrolment continues toward a full target of 40 evaluable patients.

PTX-100 is a targeted small-molecule compound designed to block geranylgeranyl transferase-1 (GGTase-1). According to company filings, the drug disrupts oncogenic RAS pathways by preventing the activation of Rho, Rac, and Ral circuits in cancer cells, promoting apoptosis. The company stated that PTX-100 is currently understood to be the only GGTase-1 inhibitor undergoing clinical trials globally. The candidate previously demonstrated safety and clinical activity in Phase 1 trials and a PK/PD basket study, as well as positive efficacy and safety signals in a Phase 1b expansion cohort in T-cell lymphomas.

The US Food and Drug Administration has granted PTX-100 Orphan Drug Designation covering all T-cell lymphomas and Fast Track Designation for the treatment of adult patients with relapsed or refractory mycosis fungoides, the most prevalent CTCL subtype. The company noted that these designations confer tangible commercial advantages, including potential market exclusivity, development incentives, and an expedited regulatory pathway.

Prescient Therapeutics Chief Executive Officer James McDonnell stated that reaching the enrolment milestone reflects solid execution by the company’s clinical team and trial sites as the drug advances toward its next phase. The company indicated it will provide a market update following the committee’s recommendations. The December DOC review carries meaningful commercial weight as a value-inflection point that de-risks PTX-100’s path to market. A favourable readout on safety and efficacy across the two dosing arms would strengthen the case for advancing into pivotal trials and sharpen the drug’s positioning in the CTCL treatment landscape, where relapsed or refractory patients represent an underserved market with limited options.

Prescient Therapeutics is a clinical-stage oncology company listed on the Australian Securities Exchange. The company focuses on developing targeted therapies for cancer, with PTX-100 being its primary asset in clinical development.

Sources